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Strengths and limitation of this study
 ► It is the first known study to assess whether re-
searchers are clearly communicating the purposes 
of their pilot/feasibility studies to participants.
 ► It raises issues that remain unaddressed in many 
research ethics guidelines.
 ► It will be used to develop guidelines on how future 
pilot/feasibility studies can best maintain high stan-
dards of informed consent.
 ► Conducted at one centre, in Canada, with a limited 
sample size, looking at studies submitted in English.
AbStrACt
Introduction Pilot/feasibility studies assess the feasibility 
of conducting a larger study. Although researchers ought to 
communicate the feasibility objectives to their participants, 
many research ethics guidelines do not comment on how 
informed consent applies to pilot studies. It is unclear 
whether researchers and research ethics boards clearly 
communicate the purpose of pilot studies to participants 
consenting.
The primary objective of this study is to assess whether 
pilot/feasibility studies submitted for ethics approval to 
a research ethics board transparently communicate the 
purpose of the study to participants through their informed 
consent practice. A highly transparent consent practice 
entails the consent documents communicate: (1) the term 
‘pilot’ or ‘feasibility’ in the title; (2) the definition of a pilot/
feasibility study; (3) the primary objectives of the study are 
to assess feasibility; (4) the specific feasibility objectives; 
and (5) the criteria for the study to successfully lead to the 
main study. The secondary objectives are to assess whether 
there is a difference between submitted and revised 
versions of the consent documents (revisions are made 
to obtain research ethics approval), to determine factors 
associated with transparent consent practices and to assess 
the consistency with which pilot and feasibility studies 
assess feasibility outcomes as their primary objectives.
Methods and analysis This is a retrospective review of 
informed consent information for pilot/feasibility studies 
submitted to the Hamilton integrated Research Ethics 
Board, Canada. We will look at submitted and revised 
consent documents for pilot/feasibility studies submitted 
over a 14- year period. We will use descriptive statistics 
to summarise data, reporting results as percentages with 
95% CIs, and conduct logistic regression to determine 
characteristics associated with transparent consent 
practices.
Ethics and dissemination The study protocol was 
approved by the Hamilton integrated Research Ethics 
Board, and the results of this study will be submitted for 
publication in a peer- reviewed journal.
IntroduCtIon
A feasibility study is a preliminary inves-
tigation done to assess the feasibility of a 
subsequent larger study.1 A pilot study is a 
type of feasibility study in which the future 
study is implemented, or partially imple-
mented, on a small scale to assess feasibility.2 
Evidence suggests that researchers use the 
terms ‘pilot’ and ‘feasibility’ without distinc-
tion,3 and because we are interested in all 
studies assessing feasibility, we will make 
no distinction between pilot and feasibility 
studies in our investigation.
The three main reasons for conducting a 
pilot study are to assess feasibility questions- 
related to process, resources and manage-
ment.4 5 Process- related objectives assess the 
feasibility of steps that need to be taken to 
ensure the success of the main study, like 
recruitment, retention and understanding 
of data collection tools.4–6 Resource- related 
objectives assess issues of time, capacity and 
other resources that could occur in the main 
study.4–6 Management- related objectives 
assess human and data management prob-
lems that can arise in the main study, like 
identifying challenges that study personnel 
would face.4–6
However, an ethical issue remains largely 
unaddressed: the obligation of researchers 
to communicate the nature and objectives 
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of pilot studies to participants of these studies, when 
obtaining consent.6 This communication is essential in 
maintaining the rights of research participants, credibility 
of researchers and trust between researchers and partic-
ipants, as some pilot studies may not proceed to future 
studies. For instance, Lancaster et al7 found that about half 
of pilot studies published indicated that further study was 
needed, and other studies have found that the proportion 
of pilot studies that lead to larger studies is between 5% 
and 24%.3 8 Although in 2010, Thabane et al6 developed 
recommendations for communicating the objectives and 
necessary information about pilot studies to participants, 
there is a paucity of data and conversation on this issue 
in the literature. Research ethics guidelines including 
the Nuremberg Code,9 Declaration of Helsinki,10 the 
Belmont Report,11 International Conference on Harmo-
nization Good Clinical Practice12 and the International 
Ethical Guidelines for Health- related Research Involving 
Humans13 do not comment on pilot studies.6 In 2018, 
the Tri- Council Policy Statement 214 (TCPS2) was revised 
to include informed consent practices in pilot studies. 
However, other research ethics guidelines need to be 
updated to address pilot studies, because they are a 
special case in which evidence suggests that the reporting 
and methods are inadequately approached.3 6–8 With 
limited guidelines on informed consent in pilot studies, 
can we expect researchers and research ethics boards to 
adequately address this issue?
The revised TCPS2 guidelines for informed consent 
in pilot studies state that researchers have an ethical 
responsibility to communicate the purpose and nature 
of pilot studies to participants when seeking consent.14 
Currently, we do not know if researchers are effectively 
communicating the feasibility nature of pilot studies 
to their participants and obtaining an acceptable level 
of informed consent. After conducting a comprehen-
sive literature search of studies assessing practices of 
informed consent in pilot studies, we concluded that 
this issue has not been empirically investigated in the 
literature.
Participants are entitled to have honest and complete 
information about the studies they are invited to partic-
ipate in, with some exceptions, like when deception or 
waiver of consent is necessary to conduct a study, and when 
such modifications of informed consent are approved by 
an ethics committee. However, depriving participants of 
a complete understanding of the pilot studies they are 
invited to participate in has ethical implications. Thus, it 
is imperative that the issue of informed consent in pilot 
studies is investigated. The results of this study will help to 
quantify the degree of this issue at one centre and could 
lead to recommendations for all research ethics boards to 
ensure high standards of informed consent are applied to 
future pilot studies.
We hypothesise that a significant number of approved 
pilot studies across various research ethics boards do 
not communicate clearly the purpose of the study to 
their participants. This study will be the first attempt to 
obtain empirical evidence on current practice regarding 
informed consent processes in pilot and feasibility studies.
Study objectives
Our primary objective is to assess whether pilot studies 
submitted to the Hamilton integrated Research Ethics 
Board (HiREB), Canada, transparently communicate 
the purpose of the study to participants through their 
informed consent practice. A highly transparent informed 
consent practice entails the patient information docu-
ments and/or consent forms effectively communicate: 
(1) the term ‘pilot’ or ‘feasibility’ in the title of the study; 
(2) the definition of a pilot or feasibility study; (3) the 
objectives or purpose of the study are stated clearly as 
assessing feasibility; (4) the specific feasibility objectives 
of the study and (5) the criteria for the feasibility study 
to successfully lead to the main study. Thus, the primary 
objective is to assess whether pilot studies submitted to 
the HiREB for research ethics approval communicate the 
preceding characteristics within their informed consent 
forms or patient information documents. The HiREB was 
chosen as the site for this study, as it is McMaster Univer-
sity’s primary research ethics board. McMaster University 
is Canada’s most research- intensive, medical doctoral 
university,15 so the HiREB is likely to see a wide variety of 
pilot studies.
Our secondary objectives are: (1) to assess whether 
there is a difference between the submitted and revised 
versions of the informed consent forms and patient infor-
mation documents (revisions are made in order to obtain 
research ethics approval), specifically in addressing the 
issues and criterion discussed in the primary objective; 
(2) to determine methodological characteristics associ-
ated with increased reporting or inclusion of the criterion 
discussed in the primary objectives within the original 
informed consent forms and patient information docu-
ments; and (3) to assess the consistency with which feasi-
bility and pilot studies assess feasibility outcomes as their 
primary objectives.
MEthodS And AnAlySIS
Sample selection
Inclusion criteria
All pilot or feasibility studies submitted to the HiREB that 
use the term ‘pilot’ or ‘feasibility’ in their title, between 
January 2006 and December 2019 inclusive, which require 
participant consent, including both randomised and non- 
randomised pilot or feasibility studies.
Exclusion criteria
All pilot or feasibility studies that have a waiver of consent.
Sample size
We used the estimation method for a single proportion, a 
statistical approach used to determine appropriate sample 
size based on inputted values for a proportion, confi-
dence interval (CI), and margin of error to determine our 
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sample size.16 We require 196 subjects if the true propor-
tion of pilot studies that use the term ‘pilot’ or ‘feasibility’ 
in the title of the study, as stated on the consent form, is 
0.5, which will be estimated with a 95% CI of about 0.43 to 
0.57 (see the online supplementary appendix 1). If more 
than 196 studies meet the inclusion criteria, then we will 
include all of them in the analysis to decrease the width 
of the CI. If fewer than 196 studies meet the inclusion 
criteria, then based on the same proportion and a 95% CI 
of 0.40 to 0.60, a sample of 96 will be sufficient to address 
the objectives of the study (see the online supplementary 
appendix 1).
data collection
Anonymised data will be extracted from the online HiREB 
database of studies using the data abstraction form (see 
the online supplementary appendix 2) and entered into 
a password- protected Microsoft Office Excel file, on a 
password- protected computer, within a locked office at 
the study site. Data will be extracted by two independent 
reviewers for a subset of the studies and a κ value with a 
95% CI will be calculated to assess agreement. Reviewers 
will receive the same training to ensure that the data 
extraction tool is used consistently. All disagreements will 
be resolved by a third party and reasons for disagreements 
will be identified and used to update standard operating 
procedures to support consistency in future coding.
To address the primary objective of the study, we will 
collect information on both the initially submitted and 
revised participant consent forms and patient informa-
tion documents specifically: (1) whether the term ‘pilot’ 
or ‘feasibility’ is in the title of the study; (2) whether 
the definition of a pilot or feasibility study is stated; (3) 
whether the objectives or purpose of the study are stated 
clearly as to assess feasibility; (4) whether the specific 
feasibility objectives of the study are stated and (5) the 
criteria for the feasibility study to successfully lead to the 
main study are stated.
To address the secondary objectives, we will also collect 
information on the methodology, design and protocol 
of the pilot studies specifically: (1) whether the studies 
were randomised or not; (2) whether the data collected 
were qualitative or quantitative (or both); (3) the desired 
sample size; (4) the year of original submission to the 
HiREB; (5) whether the study was reviewed by HiREB 
panel A, B or unidentified; (6) whether the study was 
observational or interventional; (7) the study’s source 
of funding; (8) whether the study was approved or not; 
(9) whether the study was labelled a ‘pilot’ or ‘feasibility’ 
study (or both); and (10) the specific feasibility objectives 
of the studies.
Please see the online supplementary appendix 2 for the 
full data abstraction form.
data analysis
Descriptive statistics will be used to summarise the char-
acteristics of the studies, including information on the 
methodology, design and protocol of the studies. These 
statistics will be reported as counts (percent) or mean (SD) 
and presented in tables. Results from the primary analysis 
will be used to determine the percentages of studies in 
the sample that reported each item (from the primary 
objective) and the average number of items reported, 
with the corresponding 95% CI. For the secondary objec-
tives, we will use logistic regression to analyse the data and 
assess the proportion of studies labelled ‘pilot’ or ‘feasi-
bility’ primarily assessing feasibility, with a 95% CI. Please 
see the table in the online supplementary appendix 3 for 
details and a full summary of the analysis plan. All anal-
yses will be performed using SAS V.9.2.
Please see the online supplementary appendix 3 for a 
summary of the study objectives and data analysis.
Patient and public involvement
No patients were involved in the development of this 
study.
EthICS And dISSEMInAtIon
Ethics approval and ethical concerns
The study protocol was approved by the HiREB (project 
no.: 7071 C), which granted a waiver of consent for the 
research team to access the files and consent forms from 
pilot and feasibility studies submitted to the HiREB.
dissemination
The results of this study and any ancillary studies will be 
submitted for publication in peer- reviewed journals, inde-
pendent of their statistical significance and in a timely 
manner. Furthermore, the results of this study will be used 
to develop guidelines on the best practices for the devel-
opment of consent forms in pilot studies. Although this is 
a single- centre study, if issues of transparency exist, then 
they likely extend to other research ethics boards and 
by establishing some evidence- based guideline, we may 
be able to help researchers and research ethics boards 
maintain higher standards of informed consent in pilot 
studies. Our findings will also be made available through 
conference abstracts, statistical workshops, online sources 
and to research ethics boards. The complete data set will 
only be accessible by the research team, but requests for 
the use of this information in secondary publications and 
collaborations are encouraged.
dISCuSSIon
Challenges surrounding informed consent have existed 
for many years. With the advent of new research methods, 
like pilot, biobank and online studies, new challenges 
emerge in the consent process.6 17–19 Some of these chal-
lenges, like issues related to consent in biobanks, raise 
concerns that truly informed consent is an ethical aspi-
ration rather than an ethical requirement.17
In making decisions on informed consent, it is 
important to consider its purpose. Dickert identified 
seven functions of informed consent: (1) providing 
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transparency; (2) allowing control and authorisation; 
(3) promoting concordance with participants’ values; 
(4) protecting and promoting welfare interests; (5) 
promoting trust; (6) satisfying regulatory requirements 
and (7) promoting integrity in research. The first four 
functions apply more to the individual participants, 
whereas the latter three focus on policy and systemic 
functions, with each function existing to a degree.20 
Innovative approaches to informed consent suggest 
making context- dependent informed consent forms, 
in which certain information like that which is delib-
erately communicated outside the consent documents 
is omitted.20 However, regardless of context, consent 
forms ought to convey the purpose of the research 
being conducted, as they are essential in fulfilling five 
of the seven functions of informed consent: providing 
transparency, promoting concordance with partici-
pants’ values, promoting trust, satisfying regulatory 
requirements and promoting integrity in research. 
Thus, when it comes to pilot studies, their purpose, 
although complex and nuanced, needs to be communi-
cated to participants in order to maintain the functions 
of informed consent.
If researchers are not clearly communicating the 
purposes of their pilot studies to participants, then 
there is great potential for risk and unquantifiable 
harm, as study participants’ rights can be violated, 
researchers’ credibility damaged and trust between 
participants and researchers broken. For example, if 
a participant of a pilot study discovers that they were 
lied to about the objectives of the research they agreed 
to participate in, they could feel betrayed; question 
the integrity of researchers; decide not to participate 
in future studies; question the integrity of research and 
evidenced- based medicine; and even take legal action 
against researchers, research sponsors or research ethics 
committees.This single- centre study will be the first to 
empirically measure whether researchers and research 
ethics boards are applying the general principles of 
informed consent, as highlighted by various research 
ethics guidelines,9–14 to pilot studies. Regardless of the 
results of this study, it is important to acknowledge that 
research ethics guidelines need an update, one that 
addresses informed consent in pilot studies specifically. 
We urge other institutions to conduct similar quality 
assurance projects to better quantify issues surrounding 
informed consent in pilot studies and encourage a 
timely change to research ethics guidelines.
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